Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Given the poor prognosis and limited treatment options available for patients with mucosal or
acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT
mutations in these cancers present the need to test multi-targeted kinase inhibitors with
potent KIT inhibitory activity in this patient population. Imatinib and other tyrosine kinase
inhibitors (TKIs) have the potential to be effective in this patient population, but patients
may develop resistance to treatment. Therefore, in this study, we propose to test nilotinib
in patients with metastatic mucosal, acral, or chronically sun-damaged melanoma following
treatment with another TKI.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital Novartis